The pathogenesis of demyelinating myelitis is still unclear, and it is considered to be generally related to abnormalities in the immune system. It cannot be completely cured clinically, but can only be treated to reduce symptoms, shorten the course of the disease, improve the degree of disability and prevent complications, and reduce the recurrence rate. Treatment is divided into acute attack treatment, remission treatment and symptomatic treatment. 1. Acute exacerbation treatment: glucocorticoid treatment: high-dose methylprednisolone shock therapy is preferred, which can reduce the inflammatory reaction and promote the alleviation of the disease; plasma replacement: it is suitable for patients with poor response to hormone shock therapy; intravenous immunoglobulin: it is suitable for patients without plasma replacement; hormone combined with immunosuppressant treatment: it is suitable for patients with poor effect of hormone shock. 2. Treatment in remission: mainly through the suppression of the immune system to reduce the recurrence rate and delay the accumulation of disability, long-term treatment is required. Commonly used drugs are azathioprine, morphimecrolimus, rituximab, methotrexate, cyclophosphamide, etc. The common adverse effects are gastrointestinal symptoms and decreased immune function. 3. Symptomatic treatment: oral amantadine, modafinil, etc. can be taken to relieve fatigue symptoms; taking solinacin, tolterodine to relieve the symptoms of bladder dysfunction; for patients with acute pain can be used carbamazepine, phenytoin sodium, etc.; for patients with cognitive disorders, can be used for donepezil and cognitive rehabilitation; patients with depression can be used to treat with 5-hydroxytryptamine reuptake inhibitors. For patients with demyelinating myelitis, they should go to the relevant departments of regular hospitals to avoid delays and adverse consequences.